Heart valve patients may benefit from managing own blood thinners

November 10, 2015

Chicago, 10 November 2105 - Allowing select patients to self-manage blood thinners following heart valve surgery may lead to a lower risk of major complications, according to an article posted online by the Annals of Thoracic Surgery.

Key Points:Two kinds of heart valves are available for patients undergoing valve replacement surgery. Biological valves are made from animal tissue and have the potential to wear out, especially in younger patients. Mechanical valves are made of metal and do not wear out, but require anticoagulation therapy (blood thinners) to help prevent blood clots, which could lead to strokes. The only anticoagulants currently available to these patients are vitamin K antagonists, such as warfarin or phenprocoumon.

"Oral anticoagulation therapy is usually monitored by laboratory analysis of the patient's blood, which health care providers use to determine the appropriate dosage of medication," said Thomas Decker Christensen, MD, PhD, from Aarhus University Hospital in Denmark, who led the study. "We believe that allowing patients to have more control over their own treatment can improve the standard of care in this patient group."

Dr. Christensen and colleagues evaluated the use of patient self-management of anticoagulation therapy at two hospitals in Denmark between 1996 and 2012 and compared it to the standard management. Their study included 615 patients with mechanical heart valves who self-managed treatment and 3,075 control patients (a 5:1 ratio) who received standard treatment management following valve surgery.

Patients were required to attend an educational program containing a minimum of three teaching lessons in order to be eligible for self-management. Over a period of 27 weeks following the educational training, patients gradually became self-managed.

"Once patients were approved for self-management, they were allowed to continue as such but could contact the treatment center with questions or concerns," said Dr. Christensen. "Patients were provided with a portable coagulometer, which they used to analyze medication levels and monitor dosage. Blood levels were measured and tracked weekly."

Patients compared their own measurements against the International Normalized Ratio, a number that explains how quickly blood clots. Based on this ratio, patients adjusted their dosage levels according to what they had been taught in the educational training.

Researchers observed low rates of adverse events among patients who transitioned to self-management. At 1 year after treatment, the risk of major bleeding and thromboembolism (a blood clot that moves through the bloodstream and blocks another vessel) were similar in both treatment groups. After 5 years, however, patients who self-managed their anticoagulants had a lower risk of all-cause mortality compared to standard management patients.

"There are several reasons that patients who self-manage treatment have better outcomes than those who follow standard management," explained Dr. Christensen. "Self-management patients receive more detailed information about oral anticoagulation therapy; they also learn more about the influence that diet, infectious diseases, alcohol, and other drug interactions can have on their treatment than do patients receiving standard management."

He added that he hopes this study will have an impact on the management and care of heart valve patients, "We believe that the majority of patients who have a mechanical heart valve inserted during surgery should be able to manage their oral anticoagulant therapy, and recommend this as the standard treatment approach for these patients."

Elsevier Health Sciences

Related Blood Thinners Articles from Brightsurf:

Benefits of high-dose blood thinners in COVID-19 patients remain unclear
While COVID-19 infected patients should be treated with standard anticoagulation therapies, such as blood thinning medication, a new study by researchers at the George Washington University shows that anticoagulating patients at higher doses, without traditional medical indications to do so, may be ineffective and even harmful. 

Children who take steroids at increased risk for diabetes, high blood pressure, blood clots
Children who take oral steroids to treat asthma or autoimmune diseases have an increased risk of diabetes, high blood pressure, and blood clots, according to Rutgers researchers.

Cardiology trial shows potential benefit of genetic testing when selecting blood thinners
An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce by 34 per cent the number of serious adverse events following balloon angioplasty, a treatment for the most common form of heart disease.

Transient increase in blood pressure promotes some blood vessel growth
Blood vessels are the body's transportation system, carrying oxygen and nutrients to cells and whisking away waste.

Blood thinners may improve survival among hospitalized COVID-19 patients
Research could change standard of care protocols to prevent clotting associated with coronavirus.

Brain blood flow sensor discovery could aid treatments for high blood pressure & dementia
A study led by researchers at UCL has discovered the mechanism that allows the brain to monitor its own blood supply, a finding in rats which may help to find new treatments for human conditions including hypertension (high blood pressure) and dementia.

Study: Blood-clotting protein and blood platelets promote immune evasion, cancer progression
A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G.

How high levels of blood fat cause inflammation and damage kidneys and blood vessels
Viral and bacterial infections are not the only causes of inflammation of body tissue.

Should patients continue blood thinners after experiencing gastrointestinal bleeding?
Anticoagulants and antiplatelet drugs, which are blood thinners such as warfarin and aspirin, are commonly taken to reduce the risk of potentially fatal blood clots, but they carry an increased risk of gastrointestinal bleeding.

Impeding white blood cells in antiphospholipid syndrome reduced blood clots
A new study examined APS at the cellular level and found that two drugs reduced development of blood clots in mice affected with the condition.

Read More: Blood Thinners News and Blood Thinners Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.